ANTIEPILEPTIC DRUG UTILIZATION AND MEDICAID REIMBUSEMENT TRENDS FROM 1991 TO 2008

Author(s)

Tundia N, Guo JJ, Wigle P, Heaton PUniversity of Cincinnati, Cincinnati, OH, USA

OBJECTIVES: Antiepileptic drugs (AEDs) are one of the most frequently prescribed medication classes in U.S. The objectives of this study were to describe AED utilization, price and reimbursement trends and to analyze the market share competition between traditional and newer AEDs. METHODS: A retrospective, descriptive time-series analysis was performed using the National Medicaid pharmacy claims database from 1991 to 2008.  Quarterly number of prescriptions and reimbursement data were calculated for the trends analysis.  Study drugs included all brand and generic names of newer AEDs (e.g., gabapentin, lamotrigine, topiramate, fosphenytoin) and traditional AEDs (e.g., tiagabine, valproate, zonisamide, carbamzepine). Market share for AEDs was quantified annually. The quarterly price per prescription was calculated by dividing the total reimbursement by the total number of prescriptions. RESULTS: The total number of newer AED prescriptions increased from 32,837 prescriptions totaling $2.2 million reimbursement in 1993 to 7.7 million totaling $1.2 billion in 2005, and dropped to 4.3 million totaling $847 million in 2008.  Meanwhile, traditional AED prescriptions increased from 5.14 million totaling $154 million reimbursement in 1991 to 20.5 million totaling $1.22 billion in 2004, and dropped to 11.5 million totaling $447 million in 2008. The average annual increase in number of prescriptions was 71.3% for newer and 6.95% for traditional AEDs. The market share of newer AED prescriptions increased from 1% in 1993 to 28% in 2005, and 27% in 2008. Fosphenytoin remained the most expensive newer AED with price of $211 in 1996 and $391 in 2005. Valproic acid and clorazepate were the most expensive traditional AEDs, with prices varying from $150 to $600.     CONCLUSIONS: There has been substantial increase in use of AED, which may be due to off-label use, new indications, and as adjunct therapy. A significant drop in AED utilization trends since 2004 may potentially be due to Medicare part D introduction and patent expiration.

Conference/Value in Health Info

2010-05, ISPOR 2010, Atlanta, GA, USA

Value in Health, Vol. 13, No. 3 (May 2010)

Code

PND35

Topic

Economic Evaluation, Health Policy & Regulatory, Health Service Delivery & Process of Care

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Prescribing Behavior, Pricing Policy & Schemes

Disease

Neurological Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×